COVID-19
Conditions
Keywords
COVID-19, SARS-CoV-2, vaccine, immunization
Brief summary
This is an open-label, randomized, parallel-controlled clinical trial conducted in people aged 18 years and older to evaluate the immunogenicity and safety of two SARS-CoV-2 bivalent vaccines constructed by adenovirus type 5-based or mRNA-based technics.
Detailed description
The clinical trial plans to recruit 450 subjects aged 18 years and above with an interval of ≥ 3 months between the previous dose of SARS-CoV-2 vaccine immunization and receive one dose of inhaled prototype strain and omicron BA.4/5 bivalent recombinant SARS-CoV-2 vaccine (adenovirus vector type 5) (Ad5-NCO5T-IH), beta strain and omicron BA.4/5 bivalent SARS-CoV-2 mRNA vaccine (mbO5) or inhaled prototype recombinant SARS-CoV-2 vaccine (adenovirus vector type 5) (Ad5-nCoV-IH) for follow-up until 6 months after vaccination.
Interventions
BIOLOGICALPrototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation
Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively
BIOLOGICALBivalent COVID-19 mRNA Vaccine
Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively
BIOLOGICALRecombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation
Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
Sponsors
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
Zhongnan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
In people aged 18 years and older, people were divided into in three groups and vaccinated using three kinds of vaccines: 1. Test vaccine 1: Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation 2. Test vaccine 2: Bivalent COVID-19 mRNA Vaccine 3. Control vaccine: Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Volunteers aged 18 and above at the time of screening; 2. Volunteers can provide with informed consent and sign informed consent form (ICF); 3. Have received COVID-19 vaccine, and the interval between the last vaccination ≥ 3 months.
Exclusion criteria
1. Those with convulsions, epilepsy, encephalopathy and serious neurological diseases (such as transverse myelitis, Guillain-Barre syndrome, demyelinating disease, etc.) in the past five years; 2. Those who are allergic to the active ingredient, any inactive ingredient, or substances used in the production process of the research vaccine, or those who are allergic to the similar vaccines previously; Those who have had severe allergic reactions to vaccines in the past (such as acute allergic reactions, angioedema, dyspnea, etc.), and have any previous history of severe allergies to vaccines, foods, drugs, such as: urticaria, anaphylactic shock, skin eczema, allergic dyspnea, angioedema, etc. or a history of asthma; 3. Those who have previously suffered from severe heart diseases such as myocarditis and pericarditis; 4. Those who have experienced vaccination-related hospitalization or emergency care after previous vaccination; 5. Female urine pregnancy test positive or lactating volunteers, volunteers or their partners have not taken effective contraception 2 weeks before screening or have a pregnancy plan within 6 months; 6. Fever, axillary body temperature≥ 37.3°C; 7. Those with suspected symptoms of COVID-19 in the past 3 months (fever, cough, muscle pain, loss of smell or taste, etc.); 8. Investigators judge that they have known or suspected concomitant serious diseases with unstable drug control, including: respiratory diseases, tuberculosis, acute infection or active chronic disease, liver and kidney disease, cardiovascular disease (cardiopulmonary failure), hypertension (systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥100 mmHg), malignant tumors, infectious or allergic skin diseases; 9. No spleen or functional spleen; 10. Thrombocytopenia, bleeding disorders, or other coagulation disorders (which may cause contraindications to intramuscular injection); 11. Immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, superficial corticosteroid therapy for acute non-complicated dermatitis) in the past 6 months; 12. Suffering from nasal or oral diseases, such as acute rhinitis (sinusitis), allergic rhinitis, mouth ulcers, throat redness and swelling, etc.; 13. Have received blood products within 3 months prior to receiving the test vaccine; 14. Have received other vaccines or investigational drugs within 1 month prior to receiving the test vaccine; 15. Are receiving anti-tuberculosis treatment; 16. Those with a history of COVID-19 infection in the past 3 months; 17. Those who have a positive test result of the novel coronavirus antigen at the time of screening; 18. Those with positive HIV infection results at screening; 19. Participated in other interventional studies of lipid-containing nanoparticles; 20. According to the judgment of the investigator, due to various medical, psychological, social or other conditions, it is contrary to the trial protocol, or affects the volunteers' signing of informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-XBB-specific neutralizing antibody | on day 28 post vaccination | GMT of anti-XBB-specific neutralizing antibody on day 28 post vaccination |
| The incidence of adverse reactions | within 28 days post vaccination | The incidence of adverse reactions within 28 days post vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of SAE and AESI | within 6 months post vaccination | The incidence of SAE and AESI within 6 months post vaccination |
| The incidence of adverse reactions | within 30 mins post vaccination | The incidence of adverse reactions within 30 mins post vaccination |
| specific neutralizing antibody against XBB and BA.5 variant at 14 days, 3 and 6 months | at 14 days, 3 and 6 months | The positive conversion rate, GMT and GMI of specific neutralizing antibody against XBB and BA.5 variant from first 90 subjects at 14 days, 3 and 6 months |
| specific neutralizing antibody against XBB and BA.5 variant on 0 and 28 days | on 0, 28 days post vaccination | The positive conversion rate, GMT and GMI of specific neutralizing antibody against XBB and BA.5 variant on 0 and 28 days |
| The incidence of adverse event | within 28 days post vaccination | The incidence of adverse event within 28 days post vaccination |
Countries
China
Contacts
Primary ContactJianying Huang
Backup ContactJianyuan Wu
Outcome results
None listed